SYFOVRE\u2122 (pegcetacoplan injection) is the first and only approved therapy for geographic atrophy (GA). By targeting C3, SYFOVRE is designed to provide comprehensive control of the complement cascade, part of the body\u2019s immune system. SYFOVRE is approved in the United States for the treatment of GA secondary to age-related macular degeneration.<\/p>\n
U.S. Food and Drug Administration (FDA) has approved SYFOVRE\u2122 (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). SYFOVRE is the first and only FDA-approved treatment for GA, a leading cause of blindness that impacts more than one million people in the U.S. and five million people worldwide.<\/p>\n
GA is an advanced form of AMD. It is a progressive and irreversible disease caused by the growth of lesions, which destroy the retinal cells responsible for vision. The vision loss caused by GA severely impairs independence and quality of life by making it difficult to participate in daily activities. On average, it takes only 2.5 years for GA lesions to start impacting the fovea, which is responsible for central vision.<\/p>\n
If SYFOVRE (pegcetacoplan injection)\u00a0<\/strong>are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n Note:<\/strong><\/em> Syfovre injection is used\u00a0to treat geographic atrophy (GA)<\/b>, which is the dry, advanced form of age-related macular degeneration (AMD). Syfovre injection works to slow the growth of GA lesions and to help preserve vision by reducing more significant vision loss and blindness.<\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"SYFOVRE (pegcetacoplan) injection, for intravitreal use
\nInitial U.S. Approval: 2021<\/h2>\n